Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8 + T cells without host preconditioning
Conclusions:
Collectively, our results identify how and when to administer TLR agonists to augment T cell-based immunotherapy in the absence or presence of host preconditioning for treatment of advanced malignancies. Our findings have clinical implications for the design of next generation immune-based therapies for patients with cancer.
Source: Epidemiologic Perspectives and Innovations - Category: Epidemiology Authors: Michelle NelsonJacob BowersStefanie BaileyMarshall DivenCaroline FugleAndrew KaiserClaudia WrzesinskiBei LiuNicholas RestifoChrystal Paulos Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Epidemiology | Immunotherapy | Melanoma | Skin Cancer | Toxicology | Vaccines